BridgeBio Oncology Therapeutics (BBOT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 16, 2026, to elect two Class I directors and ratify the appointment of Deloitte & Touche LLP as the independent auditor for 2026.

• Only stockholders of record as of April 20, 2026, are entitled to vote; 80,112,725 shares of common stock are outstanding and eligible.

• Voting can be done online, by phone, by mail, or during the virtual meeting; proxies will be voted per board recommendations if no instructions are given.

• The company uses internet delivery of proxy materials to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Proposals include electing two Class I directors (Frank McCormick and Peter Lebowitz) and ratifying Deloitte & Touche LLP as auditor.

• Board recommends voting FOR both director nominees and FOR auditor ratification.

• Shareholders may submit proposals for the 2027 meeting between February 16 and March 18, 2027; proposals for proxy inclusion are due by December 29, 2026.

• Procedures for advance notice and eligibility for shareholder proposals and nominations are detailed.

Board of directors and corporate governance

• Board consists of eight members divided into three staggered classes; majority are independent per Nasdaq and SEC rules.

• Board leadership is separated between Executive Chair, Chair, and CEO roles.

• Committees include audit, compensation, and nominating/corporate governance, each with defined charters and independence requirements.

• Code of Business Conduct and Ethics applies to all directors, officers, and employees.

• Directors and officers are indemnified to the fullest extent permitted by Delaware law; liability insurance is maintained.